FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317435013> ?p ?o ?g. }

• W4317435013 endingPage "587" @default.
• W4317435013 startingPage "587" @default.
• W4317435013 abstract "Glioblastoma (GBM) is an aggressive brain cancer associated with poor overall survival. The metabolic status and tumor microenvironment of GBM cells have been targeted to improve therapeutic strategies. TLR4 is an important innate immune receptor capable of recognizing pathogens and danger-associated molecules. We have previously demonstrated the presence of TLR4 in GBM tumors and the decreased viability of the GBM tumor cell line after lipopolysaccharide (LPS) (TLR4 agonist) stimulation. In the present study, metformin (MET) treatment, used in combination with temozolomide (TMZ) in two GBM cell lines (U87MG and A172) and stimulated with LPS was analyzed. MET is a drug widely used for the treatment of diabetes and has been repurposed for cancer treatment owing to its anti-proliferative and anti-inflammatory actions. The aim of the study was to investigate MET and LPS treatment in two GBM cell lines with different metabolic statuses. MET treatment led to mitochondrial respiration blunting and oxidative stress with superoxide production in both cell lines, more markedly in U87MG cells. Decreased cell viability after MET + TMZ and MET + LPS + TMZ treatment was observed in both cell lines. U87MG cells exhibited apoptosis after MET + LPS + TMZ treatment, promoting increased ER stress, unfolded protein response, and BLC2 downregulation. LPS stimulation of U87MG cells led to upregulation of SOD2 and genes related to the TLR4 signaling pathway, including IL1B and CXCL8. A172 cells attained upregulated antioxidant gene expression, particularly SOD1, TXN and PRDX1-5, while MET treatment led to cell-cycle arrest. In silico analysis of the TCGA-GBM-RNASeq dataset indicated that the glycolytic plurimetabolic (GPM)-GBM subtype had a transcriptomic profile which overlapped with U87MG cells, suggesting GBM cases exhibiting this metabolic background with an activated inflammatory TLR4 pathway may respond to MET treatment. For cases with upregulated CXCL8, coding for IL8 (a pro-angiogenic factor), combination treatment with an IL8 inhibitor may improve tumor growth control. The A172 cell line corresponded to the mitochondrial (MTC)-GBM subtype, where MET plus an antioxidant inhibitor, such as anti-SOD1, may be indicated as a combinatory therapy." @default.
• W4317435013 created "2023-01-19" @default.
• W4317435013 creator A5002549318 @default.
• W4317435013 creator A5007458912 @default.
• W4317435013 creator A5014723606 @default.
• W4317435013 creator A5028308827 @default.
• W4317435013 creator A5049756380 @default.
• W4317435013 creator A5051701249 @default.
• W4317435013 creator A5057411459 @default.
• W4317435013 creator A5063428489 @default.
• W4317435013 date "2023-01-18" @default.
• W4317435013 modified "2023-10-17" @default.
• W4317435013 title "GBM Cells Exhibit Susceptibility to Metformin Treatment According to TLR4 Pathway Activation and Metabolic and Antioxidant Status" @default.
• W4317435013 cites W1893588436 @default.
• W4317435013 cites W1970094644 @default.
• W4317435013 cites W1975153105 @default.
• W4317435013 cites W1976993918 @default.
• W4317435013 cites W1979100644 @default.
• W4317435013 cites W1988622893 @default.
• W4317435013 cites W1992313984 @default.
• W4317435013 cites W2022492842 @default.
• W4317435013 cites W2042259492 @default.
• W4317435013 cites W2045594601 @default.
• W4317435013 cites W2060839127 @default.
• W4317435013 cites W2096287682 @default.
• W4317435013 cites W2102278945 @default.
• W4317435013 cites W2131180390 @default.
• W4317435013 cites W2141545183 @default.
• W4317435013 cites W2142919879 @default.
• W4317435013 cites W2145506897 @default.
• W4317435013 cites W2149441684 @default.
• W4317435013 cites W2159707944 @default.
• W4317435013 cites W2160382843 @default.
• W4317435013 cites W2161289668 @default.
• W4317435013 cites W2427974633 @default.
• W4317435013 cites W2489294456 @default.
• W4317435013 cites W2534963778 @default.
• W4317435013 cites W2562227571 @default.
• W4317435013 cites W2580786621 @default.
• W4317435013 cites W2587210054 @default.
• W4317435013 cites W2623583708 @default.
• W4317435013 cites W2649656222 @default.
• W4317435013 cites W2744265558 @default.
• W4317435013 cites W2757027691 @default.
• W4317435013 cites W2771357379 @default.
• W4317435013 cites W2782730827 @default.
• W4317435013 cites W2808608645 @default.
• W4317435013 cites W2896973773 @default.
• W4317435013 cites W2913380930 @default.
• W4317435013 cites W2916846461 @default.
• W4317435013 cites W2934093192 @default.
• W4317435013 cites W2950595506 @default.
• W4317435013 cites W2956089932 @default.
• W4317435013 cites W2972293235 @default.
• W4317435013 cites W2985421076 @default.
• W4317435013 cites W2999105571 @default.
• W4317435013 cites W3000559384 @default.
• W4317435013 cites W3045146569 @default.
• W4317435013 cites W3093200268 @default.
• W4317435013 cites W3107527779 @default.
• W4317435013 cites W3112600195 @default.
• W4317435013 cites W3119640668 @default.
• W4317435013 cites W3123300747 @default.
• W4317435013 cites W3149245956 @default.
• W4317435013 cites W3161353558 @default.
• W4317435013 cites W3171139414 @default.
• W4317435013 cites W3174246647 @default.
• W4317435013 cites W3180256722 @default.
• W4317435013 cites W3205057133 @default.
• W4317435013 cites W4285588947 @default.
• W4317435013 cites W4293776731 @default.
• W4317435013 cites W4304688773 @default.
• W4317435013 doi "https://doi.org/10.3390/cancers15030587" @default.
• W4317435013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36765551" @default.
• W4317435013 hasPublicationYear "2023" @default.
• W4317435013 type Work @default.
• W4317435013 citedByCount "1" @default.
• W4317435013 countsByYear W43174350132023 @default.
• W4317435013 crossrefType "journal-article" @default.
• W4317435013 hasAuthorship W4317435013A5002549318 @default.
• W4317435013 hasAuthorship W4317435013A5007458912 @default.
• W4317435013 hasAuthorship W4317435013A5014723606 @default.
• W4317435013 hasAuthorship W4317435013A5028308827 @default.
• W4317435013 hasAuthorship W4317435013A5049756380 @default.
• W4317435013 hasAuthorship W4317435013A5051701249 @default.
• W4317435013 hasAuthorship W4317435013A5057411459 @default.
• W4317435013 hasAuthorship W4317435013A5063428489 @default.
• W4317435013 hasBestOaLocation W43174350131 @default.
• W4317435013 hasConcept C104317684 @default.
• W4317435013 hasConcept C126322002 @default.
• W4317435013 hasConcept C127561419 @default.
• W4317435013 hasConcept C134018914 @default.
• W4317435013 hasConcept C185592680 @default.
• W4317435013 hasConcept C190283241 @default.
• W4317435013 hasConcept C2775838275 @default.
• W4317435013 hasConcept C2776070231 @default.
• W4317435013 hasConcept C2776108821 @default.
• W4317435013 hasConcept C2776151105 @default.

• next